Myriad Genetics Reports Phase II Data on Lead Compound MPC-7869 at Recent Cancer Research Meeting

- Clinical Study in Prostate Cancer Patients Reported Safety and

Effect on PSA Progression Results -



Apr 26, 2001, 01:00 ET from Myriad Genetics, Inc.

    SALT LAKE CITY, April 26 /PRNewswire/ -- Myriad Genetics, Inc.
 (Nasdaq:   MYGN) announced today that Phase IIa clinical trial data on its lead
 cancer compound, MPC-7869 was presented at the recent annual meeting of the
 American Association for Cancer Research.
     The study by lead author Michael B. Lilly, M.D. of Loma Linda University,
 was entitled, "Multi-Dose Phase I-IIa Trial of E-7869 in Prostate Cancer
 Patients: Safety and Time to PSA Progression (TPSAP)."  The presentation
 reported 4-month findings from 23 late stage prostate cancer patients who went
 on to receive up to 32 weeks of dosing with MPC-7869.  The trial was open-
 label, using biweekly escalation of MPC-7869 oral daily dose levels.
 Generally, dose levels increased from 200mg per day to 1200 mg per day during
 the first 16 weeks.  Most patients went on to receive 800mg twice daily for an
 additional 16 weeks.  The safety and tolerance of daily oral doses was
 reported in the presentation as well as analysis of PSA level data collected
 throughout the study.
     Of the 23 prostate cancer patients enrolled, 13 had a PSA level greater
 than 5ng/ml and rising (greater than 50% increase over the prior 4-6 months)
 at entry into the study.  Of these, five (39%) had stable PSA values after
 120 days of treatment with MPC-7869.  Five of the enrolled prostate cancer
 patients had a PSA level less than 5 ng/ml that was rising at entry into the
 study.  Three of these five (60%) had less than a 50% increase in their PSA
 level through 120 days of treatment with MPC-7869.  In all, 8 of the
 18 prostate cancer patients (42%) that had rising PSA levels at study entry
 experienced either a complete stabilization in PSA level or a reduction in the
 rate of increase of their PSA level.
     The authors conclude that extended daily dosing with MPC-7869 was well-
 tolerated in late stage prostate cancer patients with a good safety profile
 and that given results of the analysis of the effect of MPC-7869 on PSA
 progression in these patients, MPC-7869 should continue to be studied in
 controlled human clinical trials for adjuvant therapy and chemoprevention of
 prostate cancer.
     "We are very pleased with these exciting results in a disease that is
 extremely difficult to treat," said Adrian Hobden, Ph.D., President of Myriad
 Pharmaceuticals, Inc.  "Currently, the only treatments available to patients
 with advanced prostate cancer are for the management of symptoms and offer
 little in terms of affecting disease progression."
     As part of the AACR presentation, previous studies with MPC-7869 in animal
 models of both prostate and colon cancer were summarized.  Results of MPC-7869
 in the TRAMP mouse model of prostate cancer supported the reported clinical
 data.  Of further interest were experiments in the APC min+/- mouse model.
 These mice develop polyps that are believed to mirror the spontaneous
 formation of polyps, which are precursors of cancerous tumors, in humans.  In
 this model, MPC-7869 reduced polyp/tumor area by approximately 99%.  All of
 the animals treated with MPC-7869 survived, versus only 27% survival among
 untreated animals.  Although 27% of the untreated animals survived the 180 day
 study period, they had extensive tumors, while all of the treated animals
 remained healthy.
     Myriad intends to take MPC-7869 through human clinical trials itself,
 retaining all rights to the drug.  Myriad is currently planning further human
 clinical trials for MPC-7869 that could be initiated later this year.
 Following a successful development process and regulatory approval to market,
 Myriad would market the MPC-7869 drug through its own oncology sales force.
 This 65-person team is currently marketing predictive medicine products, in
 the fields of breast cancer and colon cancer, to medical and surgical
 oncologists in cancer centers throughout the United States.
     Myriad Genetics, Inc. is a biopharmaceutical company focused on the
 development of novel therapeutic products derived from its proprietary genomic
 and proteomic technologies.  The Company has established two wholly owned
 subsidiaries. Myriad Pharmaceuticals, Inc. develops and intends to market
 therapeutic compounds, and Myriad Genetic Laboratories, Inc. develops and
 markets proprietary predictive medicine and personalized medicine products.
 The Company has established strategic alliances with Bayer, Eli Lilly,
 Hitachi, Novartis, Oracle, Pharmacia, Roche, Schering AG, Schering-Plough and
 Syngenta.
 
     The discussion in this news release includes forward-looking statements
 that are subject to certain risks and uncertainties.  Such statements are
 based on management's current expectations that are subject to risks and
 uncertainties that could cause actual results to differ materially from those
 set forth or implied by forward-looking statements, including, but not limited
 to uncertainties as to the extent of future government regulation of Myriad
 Genetics' or Myriad Proteomics' business, uncertainties as to whether Myriad
 Genetics or Myriad Proteomics and its collaborators will be successful in
 developing, and obtaining regulatory approval for, and commercial acceptance
 of, therapeutics; the risk that markets will not exist for therapeutic
 compounds that Myriad Genetics or Myriad Proteomics develops or if such
 markets exist, that Myriad Genetics or Myriad Proteomics will not be able to
 sell compounds, which it develops, at acceptable prices
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X10816434
 
 

SOURCE Myriad Genetics, Inc.
    SALT LAKE CITY, April 26 /PRNewswire/ -- Myriad Genetics, Inc.
 (Nasdaq:   MYGN) announced today that Phase IIa clinical trial data on its lead
 cancer compound, MPC-7869 was presented at the recent annual meeting of the
 American Association for Cancer Research.
     The study by lead author Michael B. Lilly, M.D. of Loma Linda University,
 was entitled, "Multi-Dose Phase I-IIa Trial of E-7869 in Prostate Cancer
 Patients: Safety and Time to PSA Progression (TPSAP)."  The presentation
 reported 4-month findings from 23 late stage prostate cancer patients who went
 on to receive up to 32 weeks of dosing with MPC-7869.  The trial was open-
 label, using biweekly escalation of MPC-7869 oral daily dose levels.
 Generally, dose levels increased from 200mg per day to 1200 mg per day during
 the first 16 weeks.  Most patients went on to receive 800mg twice daily for an
 additional 16 weeks.  The safety and tolerance of daily oral doses was
 reported in the presentation as well as analysis of PSA level data collected
 throughout the study.
     Of the 23 prostate cancer patients enrolled, 13 had a PSA level greater
 than 5ng/ml and rising (greater than 50% increase over the prior 4-6 months)
 at entry into the study.  Of these, five (39%) had stable PSA values after
 120 days of treatment with MPC-7869.  Five of the enrolled prostate cancer
 patients had a PSA level less than 5 ng/ml that was rising at entry into the
 study.  Three of these five (60%) had less than a 50% increase in their PSA
 level through 120 days of treatment with MPC-7869.  In all, 8 of the
 18 prostate cancer patients (42%) that had rising PSA levels at study entry
 experienced either a complete stabilization in PSA level or a reduction in the
 rate of increase of their PSA level.
     The authors conclude that extended daily dosing with MPC-7869 was well-
 tolerated in late stage prostate cancer patients with a good safety profile
 and that given results of the analysis of the effect of MPC-7869 on PSA
 progression in these patients, MPC-7869 should continue to be studied in
 controlled human clinical trials for adjuvant therapy and chemoprevention of
 prostate cancer.
     "We are very pleased with these exciting results in a disease that is
 extremely difficult to treat," said Adrian Hobden, Ph.D., President of Myriad
 Pharmaceuticals, Inc.  "Currently, the only treatments available to patients
 with advanced prostate cancer are for the management of symptoms and offer
 little in terms of affecting disease progression."
     As part of the AACR presentation, previous studies with MPC-7869 in animal
 models of both prostate and colon cancer were summarized.  Results of MPC-7869
 in the TRAMP mouse model of prostate cancer supported the reported clinical
 data.  Of further interest were experiments in the APC min+/- mouse model.
 These mice develop polyps that are believed to mirror the spontaneous
 formation of polyps, which are precursors of cancerous tumors, in humans.  In
 this model, MPC-7869 reduced polyp/tumor area by approximately 99%.  All of
 the animals treated with MPC-7869 survived, versus only 27% survival among
 untreated animals.  Although 27% of the untreated animals survived the 180 day
 study period, they had extensive tumors, while all of the treated animals
 remained healthy.
     Myriad intends to take MPC-7869 through human clinical trials itself,
 retaining all rights to the drug.  Myriad is currently planning further human
 clinical trials for MPC-7869 that could be initiated later this year.
 Following a successful development process and regulatory approval to market,
 Myriad would market the MPC-7869 drug through its own oncology sales force.
 This 65-person team is currently marketing predictive medicine products, in
 the fields of breast cancer and colon cancer, to medical and surgical
 oncologists in cancer centers throughout the United States.
     Myriad Genetics, Inc. is a biopharmaceutical company focused on the
 development of novel therapeutic products derived from its proprietary genomic
 and proteomic technologies.  The Company has established two wholly owned
 subsidiaries. Myriad Pharmaceuticals, Inc. develops and intends to market
 therapeutic compounds, and Myriad Genetic Laboratories, Inc. develops and
 markets proprietary predictive medicine and personalized medicine products.
 The Company has established strategic alliances with Bayer, Eli Lilly,
 Hitachi, Novartis, Oracle, Pharmacia, Roche, Schering AG, Schering-Plough and
 Syngenta.
 
     The discussion in this news release includes forward-looking statements
 that are subject to certain risks and uncertainties.  Such statements are
 based on management's current expectations that are subject to risks and
 uncertainties that could cause actual results to differ materially from those
 set forth or implied by forward-looking statements, including, but not limited
 to uncertainties as to the extent of future government regulation of Myriad
 Genetics' or Myriad Proteomics' business, uncertainties as to whether Myriad
 Genetics or Myriad Proteomics and its collaborators will be successful in
 developing, and obtaining regulatory approval for, and commercial acceptance
 of, therapeutics; the risk that markets will not exist for therapeutic
 compounds that Myriad Genetics or Myriad Proteomics develops or if such
 markets exist, that Myriad Genetics or Myriad Proteomics will not be able to
 sell compounds, which it develops, at acceptable prices
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X10816434
 
 SOURCE  Myriad Genetics, Inc.